FDA says trust and education critical for biosimilars

The US Food and Drug Administration (FDA) has highlighted trust and education as critical factors in ensuring patient access to biosimilars.

In a keynote address at the Generic Pharmaceutical Association’s (GPhA) annual Biosimilars Council Conference, Dr Janet Woodcock, Director of the FDA Center for Drug Evaluation and Research (CDER) emphasized the importance of education and the need for patients, providers, pharmacists and others to trust in the science that enables FDA to approve biosimilars as safe, effective alternatives to costly brand-name biologicals….

Read the full article here ->